Plant-Derived Compounds in Monogenic Epilepsies: Mechanistic Evidence, Genotype-Relevant Models, and Translational Considerations
Pharmaceuticals · 07.11.2026 · 19 (11) · 1768
DOI: 10.3390/ph19111768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 07.11.2026. Verfasst von Kuanysh Zhapar und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan.
Abstract (Originalsprache)
Monogenic epilepsies and developmental and epileptic encephalopathies are biologically heterogeneous, and evidence for plant-derived interventions ranges from ethnopharmacology to randomized clinical trials. This review critically maps that evidence using a four-level genotype-relevance framework while separating antiseizure, neuroprotective, mechanistic, and clinical endpoints. Highly purified cannabidiol (CBD) has the strongest evidence chain: antiseizure activity in Scn1a-based Dravet models is complemented by randomized clinical efficacy at the syndrome level. However, current trial evidence does not establish an SCN1A-genotype-specific treatment response. β-Caryophyllene has direct preclinical evidence in a genetically relevant Dravet model. Luteolin has direct CDKL5-model evidence for reducing microglial overactivation and improving neuronal and neurodevelopmental outcomes, but seizure-frequency or video-EEG efficacy in CDKL5 deficiency disorder has not been demonstrated. Curcumin, resveratrol, epigallocatechin-3-gallate (EGCG), quercetin, and sulforaphane are supported mainly by non-genetic seizure models and therefore remain mechanistically plausible candidates rather than validated treatments for monogenic epilepsy. Medicinal plants, crude extracts, standardized preparations, and isolated compounds are considered separately. Translational prioritization should require a reproducible genotype-associated secondary phenotype, clinically meaningful functional outcomes, achievable systemic and brain exposure, acceptable safety and drug-interaction profiles, and reproducible formulation. Plant-derived compounds should therefore be viewed as potential adjuncts to established antiseizure, syndrome-specific, and gene-directed therapies rather than substitutes.
Förderung
- Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
Zitieren
APA
Zhapar, K., Gabdulkayum, A., Satvaldina, N., Mirmanova, Z., Akilzhanova, A., & Yerezhepov, D. (2026). Plant-Derived Compounds in Monogenic Epilepsies: Mechanistic Evidence, Genotype-Relevant Models, and Translational Considerations. Pharmaceuticals, 19(11), 1768. https://doi.org/10.3390/ph19111768
Vancouver
Zhapar K, Gabdulkayum A, Satvaldina N, Mirmanova Z, Akilzhanova A, Yerezhepov D. Plant-Derived Compounds in Monogenic Epilepsies: Mechanistic Evidence, Genotype-Relevant Models, and Translational Considerations. Pharmaceuticals. 2026;19(11):1768. doi:10.3390/ph19111768
BibTeX
@article{Zhapar2026,
author = {Zhapar, Kuanysh and Gabdulkayum, Aidana and Satvaldina, Nazerke and Mirmanova, Zhanel and Akilzhanova, Ainur and Yerezhepov, Dauren},
title = {Plant-Derived Compounds in Monogenic Epilepsies: Mechanistic Evidence, Genotype-Relevant Models, and Translational Considerations},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1768},
doi = {10.3390/ph19111768}
}
EUVIMED